{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T15:09:54Z","timestamp":1783177794997,"version":"3.54.6"},"reference-count":56,"publisher":"Japanese Circulation Society","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Circ Rep"],"published-print":{"date-parts":[[2025,5,9]]},"DOI":"10.1253\/circrep.cr-25-0019","type":"journal-article","created":{"date-parts":[[2025,3,31]],"date-time":"2025-03-31T22:16:48Z","timestamp":1743459408000},"page":"350-358","source":"Crossref","is-referenced-by-count":14,"title":["Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Is an Independent Risk Factor for the Development of Ischemic Heart Disease\u3000\u2015 A 10-Year Cohort Study \u2015"],"prefix":"10.1253","volume":"7","author":[{"given":"Toshifumi","family":"Ogawa","sequence":"first","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"},{"name":"Department of Cellular Physiology and Signal Transduction, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"},{"name":"Department of Cellular Physiology and Signal Transduction, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marenao","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"},{"name":"Tanaka Medical Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukinori","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kei","family":"Nakata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"},{"name":"Department of Public Health, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidemichi","family":"Kouzu","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuma","family":"Mori","sequence":"additional","affiliation":[{"name":"Department of Immunology and Microbiology, National Defense Medical College"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Aida","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wataru","family":"Kawaharata","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Hosaka","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Surgery, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Natori Toru Internal Medicine and Diabetes Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nagisa","family":"Hanawa","sequence":"additional","affiliation":[{"name":"Department of Health Checkup and Promotion, Keijinkai Maruyama Clinic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masato","family":"Furuhashi","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"330","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Kanwal F, Neuschwander-Tetri BA, Loomba R, Rinella ME. Metabolic dysfunction-associated steatotic liver disease: Update and impact of new nomenclature on the American Association for the Study of Liver Diseases practice guidance on nonalcoholic fatty liver disease. <i>Hepatology<\/i> 2024; 79: 1212\u20131219.","DOI":"10.1097\/HEP.0000000000000670"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Wu S, Wu F, Ding Y, Hou J, Bi J, Zhang Z. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis. <i>Sci Rep<\/i> 2016; 6: 33386.","DOI":"10.1038\/srep33386"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Liu Y, Zhong GC, Tan HY, Hao FB, Hu JJ. Nonalcoholic fatty liver disease and mortality from all causes, cardiovascular disease, and cancer: A meta-analysis. <i>Sci Rep<\/i> 2019; 9: 11124.","DOI":"10.1038\/s41598-019-47687-3"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Balakrishnan M, Rehm J. A public health perspective on mitigating the global burden of chronic liver disease. <i>Hepatology<\/i> 2024; 79: 451\u2013459.","DOI":"10.1097\/HEP.0000000000000679"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Zhang P, Wang W, Mao M, Gao R, Shi W, Li D, et al. Similarities and differences: A comparative review of the molecular mechanisms and effectors of NAFLD and AFLD. <i>Front Physiol<\/i> 2021; 12: 710285.","DOI":"10.3389\/fphys.2021.710285"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. <i>Hepatology<\/i> 2023; 78: 1966\u20131986.","DOI":"10.1097\/HEP.0000000000000520"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Rinella ME, Lazarus JV, Ratziu V, Francque SM, Sanyal AJ, Kanwal F, et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. <i>Ann Hepatol<\/i> 2024; 29: 101133.","DOI":"10.1016\/j.aohep.2023.101133"},{"key":"8","unstructured":"8. European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL-EASD-EASO Clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). <i>J Hepatol<\/i> 2024; 81: 492\u2013542."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Mori K, Akiyama Y, Tanaka M, Sato T, Endo K, Hosaka I, et al. Deciphering metabolic dysfunction-associated steatotic liver disease: Insights from predictive modeling and clustering analysis. <i>J Gastroenterol Hepatol<\/i> 2024; 39: 1382\u20131393.","DOI":"10.1111\/jgh.16552"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement. <i>J Hepatol<\/i> 2020; 73: 202\u2013209.","DOI":"10.1016\/j.jhep.2020.07.045"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Mackowiak B, Fu Y, Maccioni L, Gao B. Alcohol-associated liver disease. <i>J Clin Invest<\/i> 2024; 134: e176345.","DOI":"10.1172\/JCI176345"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Chiva-Blanch G, Badimon L. Benefits and risks of moderate alcohol consumption on cardiovascular disease: Current findings and controversies. <i>Nutrients<\/i> 2019; 12: 108.","DOI":"10.3390\/nu12010108"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Koyama M, Ohnishi H, et al. High level of fatty liver index predicts new onset of diabetes mellitus during a 10-year period in healthy subjects. <i>Sci Rep<\/i> 2021; 11: 12830.","DOI":"10.1038\/s41598-021-92292-y"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Higashiura Y, Furuhashi M, Tanaka M, Takahashi S, Mori K, Miyamori D, et al. Elevated fatty liver index is independently associated with new onset of hypertension during a 10-year period in both male and female subjects. <i>J Am Heart Assoc<\/i> 2021; 10: e021430.","DOI":"10.1161\/JAHA.121.021430"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Takahashi S, Tanaka M, Furuhashi M, Moniwa N, Koyama M, Higashiura Y, et al. Fatty liver index is independently associated with deterioration of renal function during a 10-year period in healthy subjects. <i>Sci Rep<\/i> 2021; 11: 8606.","DOI":"10.1038\/s41598-021-88025-w"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Mori K, Tanaka M, Higashiura Y, Hanawa N, Ohnishi H, Furuhashi M. High fatty liver index is an independent predictor of ischemic heart disease during a 10-year period in a Japanese population. <i>Hepatol Res<\/i> 2022; 52: 687\u2013698.","DOI":"10.1111\/hepr.13790"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Furuhashi M, Muranaka A, Yuda S, Tanaka M, Koyama M, Kawamukai-Nishida M, et al. Independent association of fatty liver index with left ventricular diastolic dysfunction in subjects without medication. <i>Am J Cardiol<\/i> 2021; 158: 139\u2013146.","DOI":"10.1016\/j.amjcard.2021.07.047"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Tanaka M, Mori K, Takahashi S, Higashiura Y, Ohnishi H, Hanawa N, et al. Metabolic dysfunction-associated fatty liver disease predicts new onset of chronic kidney disease better than fatty liver or nonalcoholic fatty liver disease. <i>Nephrol Dial Transplant<\/i> 2023; 38: 700\u2013711.","DOI":"10.1093\/ndt\/gfac188"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Miyamori D, Tanaka M, Sato T, Endo K, Mori K, Mikami T, et al. Coexistence of metabolic dysfunction-associated fatty liver disease and chronic kidney disease is a more potent risk factor for ischemic heart disease. <i>J Am Heart Assoc<\/i> 2023; 12: e030269.","DOI":"10.1161\/JAHA.123.030269"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Mori K, Tanaka M, Hosaka I, Mikami T, Endo K, Hanawa N, et al. Metabolic dysfunction-associated fatty liver disease is associated with an increase in systolic blood pressure over time: Linear mixed-effects model analyses. <i>Hypertens Res<\/i> 2023; 46: 1110\u20131121.","DOI":"10.1038\/s41440-023-01179-0"},{"key":"21","doi-asserted-by":"publisher","unstructured":"21. Mori K, Tanaka M, Sato T, Akiyama Y, Endo K, Ogawa T, et al. Metabolic dysfunction-associated steatotic liver disease (SLD) and alcohol-associated liver disease, but not SLD without metabolic dysfunction, are independently associated with new onset of chronic kidney disease during a 10-year follow-up period. <i>Hepatol Res<\/i> 2024, doi:10.1111\/hepr.14097.","DOI":"10.1111\/hepr.14097"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Juanola O, Martinez-Lopez S, Frances R, Gomez-Hurtado I. Non-alcoholic fatty liver disease: Metabolic, genetic, epigenetic and environmental risk factors. <i>Int J Environ Res Public Health<\/i> 2021; 18: 5227.","DOI":"10.3390\/ijerph18105227"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. <i>Am J Kidney Dis<\/i> 2009; 53: 982\u2013992.","DOI":"10.1053\/j.ajkd.2008.12.034"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, et al. The fatty liver index: A simple and accurate predictor of hepatic steatosis in the general population. <i>BMC Gastroenterol<\/i> 2006; 6: 33.","DOI":"10.1186\/1471-230X-6-33"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Takahashi S, Tanaka M, Higashiura Y, Mori K, Hanawa N, Ohnishi H, et al. Prediction and validation of nonalcoholic fatty liver disease by fatty liver index in a Japanese population. <i>Endocr J<\/i> 2022; 69: 463\u2013471.","DOI":"10.1507\/endocrj.EJ21-0563"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. <i>Hepatology<\/i> 2006; 43: 1317\u20131325.","DOI":"10.1002\/hep.21178"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Umemura S, Arima H, Arima S, Asayama K, Dohi Y, Hirooka Y, et al. The Japanese Society of Hypertension guidelines for the management of hypertension (JSH 2019). <i>Hypertens Res<\/i> 2019; 42: 1235\u20131481.","DOI":"10.1038\/s41440-019-0284-9"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. American Diabetes Association. 2. Classification and diagnosis of diabetes. <i>Diabetes Care<\/i> 2017; 40: S11\u2013S24.","DOI":"10.2337\/dc17-S005"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Kinoshita M, Yokote K, Arai H, Iida M, Ishigaki Y, Ishibashi S, et al. Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases 2017. <i>J Atheroscler Thromb<\/i> 2018; 25: 846\u2013984.","DOI":"10.5551\/jat.GL2017"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Hamaguchi M, Kojima T, Itoh Y, Harano Y, Fujii K, Nakajima T, et al. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. <i>Am J Gastroenterol<\/i> 2007; 102: 2708\u20132715.","DOI":"10.1111\/j.1572-0241.2007.01526.x"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Staufer K, Stauber RE. Steatotic liver disease: Metabolic dysfunction, alcohol, or both? <i>Biomedicines<\/i> 2023; 11: 2108.","DOI":"10.3390\/biomedicines11082108"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. <i>Bone Marrow Transplant<\/i> 2013; 48: 452\u2013458.","DOI":"10.1038\/bmt.2012.244"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33. Suzuki K, Tamaki N, Kurosaki M, Takahashi Y, Yamazaki Y, Uchihara N, et al. Concordance between metabolic dysfunction-associated steatotic liver disease and nonalcoholic fatty liver disease. <i>Hepatol Res<\/i> 2024; 54: 600\u2013605.","DOI":"10.1111\/hepr.14011"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34. Lauridsen BK, Stender S, Kristensen TS, Kofoed KF, Kober L, Nordestgaard BG, et al. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279 013 individuals. <i>Eur Heart J<\/i> 2018; 39: 385\u2013393.","DOI":"10.1093\/eurheartj\/ehx662"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35. Dehghani Firouzabadi M, Poopak A, Sheikhy A, Dehghani Firouzabadi F, Moosaie F, Rabizadeh S, et al. Nonalcoholic fatty liver disease as a potential risk factor for cardiovascular disease in patients with type 2 diabetes: A prospective cohort study. <i>Int J Endocrinol<\/i> 2024; 2024: 5328965.","DOI":"10.1155\/2024\/5328965"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36. Liao YL, Zhu GY, Chang C. Non-alcoholic fatty liver disease increases the risk of cardiovascular disease in young adults and children: A systematic review and meta-analysis of cohort studies. <i>Front Cardiovasc Med<\/i> 2023; 10: 1291438.","DOI":"10.3389\/fcvm.2023.1291438"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37. Karajamaki AJ, Bloigu R, Kauma H, Kesaniemi YA, Koivurova OP, Perkiomaki J, et al. Non-alcoholic fatty liver disease with and without metabolic syndrome: Different long-term outcomes. <i>Metabolism<\/i> 2017; 66: 55\u201363.","DOI":"10.1016\/j.metabol.2016.06.009"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38. Ochoa-Allemant P, Marrero JA, Serper M. Racial and ethnic differences and the role of unfavorable social determinants of health across steatotic liver disease subtypes in the United States. <i>Hepatol Commun<\/i> 2023; 7: e0324.","DOI":"10.1097\/HC9.0000000000000324"},{"key":"39","unstructured":"39. Lee HH, Lee HA, Kim EJ, Kim HY, Kim HC, Ahn SH, et al. Metabolic dysfunction-associated steatotic liver disease and risk of cardiovascular disease. <i>Gut<\/i> 2024; 73: 533\u2013540."},{"key":"40","doi-asserted-by":"crossref","unstructured":"40. Mukamal KJ, Conigrave KM, Mittleman MA, Camargo CA Jr, Stampfer MJ, Willett WC, et al. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men. <i>N Engl J Med<\/i> 2003; 348: 109\u2013118.","DOI":"10.1056\/NEJMoa022095"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41. Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow SL, et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A scientific statement from the American Heart Association. <i>Circulation<\/i> 2023; 148: 1982\u20132004.","DOI":"10.1161\/CIR.0000000000001191"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42. Larkin H. Here\u2019s what to know about cardiovascular-kidney-metabolic syndrome, newly defined by the AHA. <i>JAMA<\/i> 2023; 330: 2042\u20132043.","DOI":"10.1001\/jama.2023.22276"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43. Claudel SE, Verma A. Cardiovascular-kidney-metabolic syndrome: A step toward multidisciplinary and inclusive care. <i>Cell Metab<\/i> 2023; 35: 2104\u20132106.","DOI":"10.1016\/j.cmet.2023.10.015"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44. Gao C, Gao S, Zhao R, Shen P, Zhu X, Yang Y, et al. Association between systemic immune-inflammation index and cardiovascular-kidney-metabolic syndrome. <i>Sci Rep<\/i> 2024; 14: 19151.","DOI":"10.1038\/s41598-024-69819-0"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45. Sebastian SA, Padda I, Johal G. Cardiovascular-kidney-metabolic (CKM) syndrome: A state-of-the-art review. <i>Curr Probl Cardiol<\/i> 2024; 49: 102344.","DOI":"10.1016\/j.cpcardiol.2023.102344"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46. Guldan M, Unlu S, Abdel-Rahman SM, Ozbek L, Gaipov A, Covic A, et al. Understanding the role of sex hormones in cardiovascular kidney metabolic syndrome: Toward personalized therapeutic approaches. <i>J Clin Med<\/i> 2024; 13: 4354.","DOI":"10.3390\/jcm13154354"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47. Jankowski J, Floege J, Fliser D, Bohm M, Marx N. Cardiovascular disease in chronic kidney disease: Pathophysiological insights and therapeutic options. <i>Circulation<\/i> 2021; 143: 1157\u20131172.","DOI":"10.1161\/CIRCULATIONAHA.120.050686"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48. Zoccali C, Mallamaci F, Adamczak M, de Oliveira RB, Massy ZA, Sarafidis P, et al. Cardiovascular complications in chronic kidney disease: A review from the European Renal and Cardiovascular Medicine Working Group of the European Renal Association. <i>Cardiovasc Res<\/i> 2023; 119: 2017\u20132032.","DOI":"10.1093\/cvr\/cvad083"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49. Anand SK, Governale TA, Zhang X, Razani B, Yurdagul A Jr, Pattillo CB, et al. Amino acid metabolism and atherosclerotic cardiovascular disease. <i>Am J Pathol<\/i> 2024; 194: 510\u2013524.","DOI":"10.1016\/j.ajpath.2023.12.006"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50. Dai Y, Junho CVC, Schieren L, Wollenhaupt J, Sluimer JC, van der Vorst EPC, et al. Cellular metabolism changes in atherosclerosis and the impact of comorbidities. <i>Front Cell Dev Biol<\/i> 2024; 12: 1446964.","DOI":"10.3389\/fcell.2024.1446964"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51. Knol MGE, Wulfmeyer VC, Muller RU, Rinschen MM. Amino acid metabolism in kidney health and disease. <i>Nat Rev Nephrol<\/i> 2024; 20: 771\u2013788.","DOI":"10.1038\/s41581-024-00872-8"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52. Mitrofanova A, Merscher S, Fornoni A. Kidney lipid dysmetabolism and lipid droplet accumulation in chronic kidney disease. <i>Nat Rev Nephrol<\/i> 2023; 19: 629\u2013645.","DOI":"10.1038\/s41581-023-00741-w"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53. Ciardullo S, Cannistraci R, Muraca E, Zerbini F, Perseghin G. Liver fibrosis, NT-ProBNP and mortality in patients with MASLD: A population-based cohort study. <i>Nutr Metab Cardiovasc Dis<\/i> 2024; 34: 963\u2013971.","DOI":"10.1016\/j.numecd.2023.11.011"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54. Li C, Wang T, Song J. A review regarding the article \u2018Electrocardiographic abnormalities in patients with metabolic dysfunction-associated Steatotic liver disease: A systematic review and meta-analysis\u2019. <i>Curr Probl Cardiol<\/i> 2024; 49: 102626.","DOI":"10.1016\/j.cpcardiol.2024.102626"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55. Kokkorakis M, Boutari C, Hill MA, Kotsis V, Loomba R, Sanyal AJ, et al. Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges. <i>Metabolism<\/i> 2024; 154: 155835.","DOI":"10.1016\/j.metabol.2024.155835"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56. Yamagishi K, Ikeda A, Iso H, Inoue M, Tsugane S, Group JS. Self-reported stroke and myocardial infarction had adequate sensitivity in a population-based prospective study JPHC (Japan Public Health Center)-based Prospective Study. <i>J Clin Epidemiol<\/i> 2009; 62: 667\u2013673.","DOI":"10.1016\/j.jclinepi.2008.07.016"}],"container-title":["Circulation Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/5\/7_CR-25-0019\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,10]],"date-time":"2025-05-10T03:15:37Z","timestamp":1746846937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/circrep\/7\/5\/7_CR-25-0019\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,9]]},"references-count":56,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1253\/circrep.cr-25-0019","relation":{},"ISSN":["2434-0790"],"issn-type":[{"value":"2434-0790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,9]]},"article-number":"CR-25-0019"}}